
Chimerix CMRX
Quarterly report 2024-Q3
added 11-07-2024
Chimerix Cash Conversion Cycle 2011-2026 | CMRX
Annual Cash Conversion Cycle Chimerix
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 588 | -2.37 K | 31.4 | 53.4 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 588 | -2.37 K | -425 |
Quarterly Cash Conversion Cycle Chimerix
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 498 | 46 | - | - | 153 | 1.22 K | 275 | - | -123 | - | -46.4 | 52.6 | 38 | 60.4 | 26.1 | 27.7 | 19.3 | 22.1 | 57.8 | 16.6 | 57.5 | 78.2 | 30.3 | 6.19 | 81.6 | 25.2 | 116 | 83.2 | 171 | 227 | 139 | 73.7 | 223 | 79.3 | 150 | 71.4 | 97.7 | 53.6 | 93.5 | 8.37 | 8.16 | 10.5 | 20.7 | 25.8 | 24.8 | 28 | 26.6 | 19.9 | 3.43 | 11.5 | 11.6 | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.22 K | -123 | 93.6 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Anika Therapeutics
ANIK
|
270 | $ 14.93 | 0.88 % | $ 219 M | ||
|
Aptorum Group Limited
APM
|
-400 | $ 0.93 | 0.51 % | $ 5.07 M | ||
|
Aquestive Therapeutics
AQST
|
-172 | $ 4.14 | 0.36 % | $ 443 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 8.39 | 4.5 % | $ 230 M | ||
|
Ardelyx
ARDX
|
885 | $ 6.06 | 1.94 % | $ 1.46 B | ||
|
Arcutis Biotherapeutics
ARQT
|
158 | $ 23.93 | 1.27 % | $ 3.04 B | ||
|
Arvinas
ARVN
|
4.66 | $ 11.36 | 4.7 % | $ 805 M | ||
|
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 61.99 | 1.57 % | $ 8.29 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Assembly Biosciences
ASMB
|
25.1 | $ 29.09 | 0.28 % | $ 326 M | ||
|
Atossa Therapeutics
ATOS
|
-2.25 K | $ 5.19 | -3.36 % | $ 44.7 M | ||
|
Atara Biotherapeutics
ATRA
|
4.13 | $ 5.0 | 0.2 % | $ 62.7 M | ||
|
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
612 | $ 16.05 | 2.79 % | $ 2.16 B | ||
|
Autolus Therapeutics plc
AUTL
|
119 | $ 1.41 | -0.35 % | $ 375 M | ||
|
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | ||
|
Axon Enterprise
AXON
|
86.2 | $ 411.97 | -0.2 % | $ 31.2 B | ||
|
Aytu BioScience
AYTU
|
174 | $ 2.65 | -1.12 % | $ 16.6 M | ||
|
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
BioCardia
BCDA
|
101 | $ 1.18 | -1.67 % | $ 7.87 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
463 | $ 9.59 | 6.26 % | $ 1.98 B | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
209 | $ 9.46 | -3.47 % | $ 612 M | ||
|
BioMarin Pharmaceutical
BMRN
|
733 | $ 56.04 | 0.96 % | $ 10.7 B | ||
|
BioXcel Therapeutics
BTAI
|
-32.5 K | $ 1.18 | -0.42 % | $ 14.4 M |